Pharma: Page 57
-
Alex Wong via Getty Images
Federal coronavirus contracts dodge pricing oversight, advocacy group says
Contracts with six companies waive "march-in rights" and omit provisions that could be used to object to high drug prices. Moderna's contract, however, includes those clauses.
By Jonathan Gardner • Updated July 1, 2020 -
Permission granted by BioNTech SE
Coronavirus vaccine from Pfizer, BioNTech shows early potential
Initial data from a small study of healthy volunteers show the companies' shot can elicit immune responses against the virus.
By Ned Pagliarulo • July 1, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Sponsored by Parexel
COVID-19 and the new pragmatism
What can we learn from the COVID-19 pandemic? What does it mean for the pharmaceutical industry?
By Paul Bridges SVP Worldwide Head Regulatory & Access, Parexel and Sheela Hegde, Partner and Managing Director, Health Advances • June 30, 2020 -
FDA rejects AbbVie's eye drug, citing safety concerns
The drug, abicipar, was supposed to challenge market-leading drugs like Regneron's Eylea. But inner eye inflammation seen in clinical trials appear to have sunk its chances.
By Jacob Bell • June 26, 2020 -
Merck strikes another neuroscience deal, tapping Yumanity for 2 brain drugs
The pharma hasn't invested much in neuroscience since its Alzheimer's drug plans unraveled in 2017. Three deals in the past year, however, should help keep its options open.
By Ben Fidler • June 24, 2020 -
Courtesy of Sanofi
Sanofi's fight for a better research reputation
Competitive markets and questionable deals make it harder for Sanofi to deliver on claims it can lead in its now-favored areas of research.
By Jacob Bell • June 23, 2020 -
Courtesy of Sanofi Pasteur
Trailing leaders, Sanofi speeds coronavirus vaccine plans
The French drugmaker now intends to begin initial testing of its primary vaccine candidate in September. An expanded alliance with Translate Bio gives it rights to a back-up.
By Ned Pagliarulo • June 23, 2020 -
Courtesy of Lonza Ltd.
Deep DiveVaccines can end the coronavirus pandemic. Will every country get them?
Scientists around the world are racing to develop a coronavirus vaccine. But the factories slated to make the leading candidates are concentrated in a handful of countries, raising concerns about global access.
By Jonathan Gardner • June 23, 2020 -
Adobe/BENIS
Sponsored by West Monroe Partners & rMark BioLeveraging data and AI for better results in pharmaceutical development
Medical Affairs teams need to be able to transfer information into well understood, viable data that translates to insights.
By Robert Eubanks, Erik Brown, Jason Smith (rMark Bio), Mike Abbadessa (rMark Bio) • June 23, 2020 -
Merck gives 1st look at Phase 3 results for its Prevnar competitor
Results from two late-stage studies of V114, Merck's experimental pneumococcal conjugate vaccine, could help support a submission for approval later this year.
By Ned Pagliarulo • June 22, 2020 -
With latest Keytruda approval, Merck beats Bristol Myers to a new immunotherapy target
The FDA decision validates a genetic cancer measure known as tumor mutational burden, which has been studied in multiple trials but previously never led to an approval.
By Ben Fidler • June 17, 2020 -
Sanofi's latest investment signals long-term focus on vaccines
The new coronavirus has brought a renewed interest in vaccines. Now, Sanofi plans to spend hundreds of millions of dollars preparing for future pandemics.
By Jacob Bell • June 16, 2020 -
Courtesy of Eli Lilly
Lilly claims success in early breast cancer study, leaping past Pfizer
The results for Lilly's Verzenio come just weeks after Pfizer's drug Ibrance fell short in a similar trial, and sent shares in the Indianapolis drugmaker soaring.
By Ben Fidler • June 16, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565892277/in/album-72157713108522106/.
AstraZeneca signs new supply deals as coronavirus vaccine data nears
The drugmaker agreed to provide 400 million doses to four European countries as part of preparations to supply the world with the coronavirus vaccine it licensed from the University of Oxford.
By Ben Fidler • June 15, 2020 -
Kendall Davis / BioPharma Dive/BioPharma Dive
CureVac gets German backing for coronavirus vaccine, but says it's independent
An investment of 300 million Euros gives the German government a 23% stake in CureVac, but won't grant the country exclusive national rights to a vaccine nearing human testing.
By Jonathan Gardner • June 15, 2020 -
Courtesy of FujiFilm
Fujifilm to invest nearly $1B in Denmark biologics plant
The Japanese contract manufacturer will double capacity at a biologics plant formerly owned by Biogen.
By Kristin Jensen • June 10, 2020 -
Courtesy of Genmab A/S
AbbVie hands Genmab $750M in latest bid to grow cancer drug business
Best known for Humira, AbbVie has made a concerted effort to build its cancer drugs business, with mixed results. The Genmab alliance could take the Illinois drugmaker in a new direction.
By Ben Fidler • June 10, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Drug regulators in agreement on coronavirus vaccine trials, FDA official says
Health agencies will be under pressure to clear promising vaccines quickly. But Peter Marks, a top FDA official, said regulators will still want to see large trials to provide proof of safety.
By Jonathan Gardner , Ben Fidler • June 9, 2020 -
China's Innovent buys rights to Roche cancer technology
The deal covers research into cell therapies and bispecific antibodies, and grants Roche an option to develop any resulting product outside of China.
By Jonathan Gardner • June 9, 2020 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
AstraZeneca, already a leader in coronavirus vaccine race, steps up antibody drug work
The British drugmaker has licensed six potential COVID-19 antibodies from Vanderbilt, and could start testing the first of them by early August.
By Ben Fidler • June 9, 2020 -
Brian Tucker/BioPharma Dive
Deep DiveCoronavirus vaccines are rolling out quickly. Here's where the pipeline stands.
Fuller data in hand, Pfizer and BioNTech plan to soon seek full U.S. approval for their vaccine in 12- to 15-year-olds.
By Ned Pagliarulo, Jonathan Gardner, Shoshana Dubnow, Ben Fidler, Nami Sumida • Updated Nov. 24, 2021 -
FGC/Shutterstock.com
Sponsored by ZSRepurposing pharma's field force in a time of 'business unusual'
Because the future is uncertain, companies don't have the luxury of designing structural changes in advance, and instead must focus on having the right capabilities, skillsets and talent in place.
By Jude Konzelmann. Co-authors: Chris Morgan & Mike Jakymiw • June 9, 2020 -
AstraZeneca reaches deals with health charities to supply coronavirus vaccine worldwide
A separate agreement with India's Serum Institute aims to provide 1 billion doses of the experimental vaccine to low- and middle-income countries.
By Jonathan Gardner • June 4, 2020 -
Permission granted by BioNTech SE
'Warp Speed' push for coronavirus vaccine accelerates as White House reportedly narrows field
The U.S. government aims to have a vaccine ready by the end of this year or early next, and appears to be counting on large drugmakers like J&J, Pfizer and Merck to deliver on that highly ambitious goal.
By Ned Pagliarulo • June 4, 2020 -
Jacob Bell/BioPharma Dive
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA
The deal follows similar pacts involving Merck, Biogen, Roche and others, reflecting growing interest by pharmaceutical companies in the emerging field.
By Ben Fidler • June 4, 2020
Previous
